TrialThe Lancet. Haematology2017

Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial.

Preetesh Jain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.